Guardant Health (NASDAQ:GH) Director Steve Krognes Sells 9,294 Shares

Posted by Brian Himes on Jun 6th, 2026

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) Director Steve Krognes sold 9,294 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $132.51, for a total value of $1,231,547.94. Following the transaction, the director directly owned 10,222 shares in the company, valued at approximately $1,354,517.22. This represents a 47.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Guardant Health Stock Down 5.6%

Shares of Guardant Health stock opened at $125.61 on Friday. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $134.28. The firm has a market cap of $16.66 billion, a PE ratio of -37.05 and a beta of 1.61. The business’s fifty day moving average is $99.39 and its two-hundred day moving average is $101.08.

Institutional Trading of Guardant Health

Several large investors have recently added to or reduced their stakes in GH. Alyeska Investment Group L.P. acquired a new stake in Guardant Health in the 3rd quarter valued at $114,421,000. Price T Rowe Associates Inc. MD increased its holdings in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares in the last quarter. Norges Bank acquired a new stake in Guardant Health in the 4th quarter valued at $128,499,000. Summit Partners Public Asset Management LLC increased its holdings in Guardant Health by 674.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock valued at $87,019,000 after purchasing an additional 741,958 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Guardant Health by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after purchasing an additional 606,368 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GH has been the topic of several research reports. Evercore raised Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price on the stock in a research report on Tuesday. Leerink Partners increased their target price on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. JPMorgan Chase & Co. increased their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Finally, Citigroup increased their target price on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $137.80.

Read Our Latest Analysis on Guardant Health

Guardant Health Company Profile

(Get Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.